Showing 961-970 of 1614 results for "".
- New App Allows Surgeons to Search for FDA Approved IOLshttps://modernod.com/news/new-app-allows-surgeons-to-search-for-fda-approved-iols/2480969/Matt Hirabayashi, MD, of eyeflymd.com, and Gurpal Virdi, MD, of Eyelabs.ai, have developed an app called “eyeSpace,” which is designed to allow surgeons and trainees to
- Pioneering Ophthalmologist William J. Lahners Passes Awayhttps://modernod.com/news/pioneering-ophthalmologist-william-j-lahners-passes-away/2480517/William J. Lahners, MD, FACS, Medical Director, Center for Sight, in Sarasota, Florida, passed away on Friday at the age of 53.
- Market Scope: Lens-Based Procedures Will Push Retail Refractive Surgery Market to $12 Billionhttps://modernod.com/news/market-scope-lens-based-procedures-will-push-retail-refractive-surgery-market-to-12-billion/2481338/Market Scope forecasts that the global refractive surgery industry will generate $12 billion in total retail revenue in 2027—up from $8.9 billion in 2022—for a compound growth rate of 6.2 percent. The health care research company expects revenue at the manufacturer level to
- NovaSight Announces Commercial Release of CureSight in the US; Names a New VP of Sales & Marketinghttps://modernod.com/news/novasight-introduces-curesight-to-the-us-and-names-a-new-vp-of-sales-marketing/2481295/NovaSight has announced that its CureSight digital therapy for amblyopia will be released to the US market beginning this month. CureSight received FDA 510(K) clearance based on a pivotal study that found the device to be noninferior to eye patching—t
- Eye Foundation of America Hosts Fundraising Galahttps://modernod.com/news/eye-foundation-of-america-hosts-fundraising-gala/2482734/On April 12, the Eye Foundation of America is hosting a Spring fundraiser gala in New Rochelle, New York. Under the leadership of Surendra Sharma, MD and Rachana Shukla, MD, the group hopes to raise funds to help support a new state-of-the-art green hospital in India, as well
- Oculis and Euretina Announce Winner of Inaugural Ramin Tadayoni Awardhttps://modernod.com/news/oculis-and-euretina-announce-winner-of-inaugural-ramin-tadayoni-award/2482449/Oculis, in partnership with Euretina, has announced the first recipient of the Ramin Tadayoni Award: Dr. Andrea Govetto, MD, PhD. The award honors the memory of Oculis' late Chief Scientific Officer and renowned retina specialist, Professor Ramin Tadayoni, MD, who passed away unexpectedly ear
- Inaugural Eyecelerator Innovation Award Presented to Regeneron Executiveshttps://modernod.com/news/inaugural-eyecelerator-innovation-award-presented-to-regeneron-executives/2482404/Leonard Schleifer, MD, PhD, and George Yancopoulos, MD, PhD, of Regeneron Pharmaceuticals were awarded the first Eyecelerator Innovation Award. "This year's Eyecelerator Innovation Award honors the remarkable physician-led, science-dr
- NEI Director Highlights Metabolomics as an Approach to Understanding Glaucomahttps://modernod.com/news/nei-director-highlights-metabolomics-as-an-approach-to-understanding-glaucoma/2481982/The National Eye Institute (NEI) announced that NEI Director Michael F. Chiang, MD, featured recent research by NEI grantee Louis Pasquale, MD, in a National Institute of Health Director’s Blog post. Dr. Pasquale in collaboration with Jae Hee Kang, ScD, and Oana Zeleznik, PhD, explored 369
- EyePoint Pharmaceuticals Forms Executive Scientific Advisory Boardhttps://modernod.com/news/eyepoint-pharmaceuticals-forms-executive-scientific-advisory-board/2479426/EyePoint Pharmaceuticals announced the formation of its Executive Scientific Advisory Board (SAB), chaired by Carl Regillo MD, FACS, Chief of the Retina Service at Wills Eye Hospital. Other members of the SAB include Sophie J. Bakri, MD, Mayo Clinic; Caroline R. B
- Noveome Biotherapeutics Announces Preliminary Results of its Phase 1 Trial Evaluating Intranasal Delivery of ST266 In Glaucoma Suspect Patientshttps://modernod.com/news/noveome-biotherapeutics-announces-preliminary-results-of-its-phase-1-trial-evaluating-intranasal-delivery-of-st266-in-glaucoma-suspect-patients/2479275/Noveome Biotherapeutics announced preliminary results of a phase 1 open label clinical trial to establish the safety of ST266 when delivered intranasally in glaucoma suspect patients. The trial was conducted at the University of Pennsylvania by Ahmara Ross, MD, PhD, and Kenneth Shindler, MD, PhD,